The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based Review

DFS according to the administration of autologous BMT or chemotherapy. BMT: total 96, dead 63; censored, 33. Chemotherapy: total, 95, dead 58; censored, 47. (P=.8). Reprinted with permission [5].

Disease-free survival (DFS) according to second randomization for patients in group 2 (70 patients in the autologous stem-cell transplantation [SCT] arm and 59 patients in the chemotherapy arm). CR, complete remission. Reprinted with permission [7].

Disease-free survival (DFS) according to genetic randomization. For this analysis, patients from group 2 (211 patients) and those from group 4 (48 patients) were pooled. The group with a sibling donor comprised 100 patients, whereas that with no sibling donor included 159 patients. CR, complete remission. Reprinted with permission [7].

Overall survival of patients with high-risk leukemia according to allocation arm. (Solid line BMT; dashed line control). Reprinted with permission [6].

Kaplan-Meier estimation of disease-free survival in patients receiving transplantation from a matched related or unrelated donor in first complete remission. Reprinted with permission [56].

Overall survival according to alloBMT and autoBMT in an intent-to-treat analysis. Reprinted with permission [66].

DFS was significantly superior (P < .001) for patients with an HLA-identical sibling (dashed line) than for patients without an HLA-identical sibling (solid line). Reprinted with permission [67].

Kaplan-Meier landmark survival estimates (with a 90-day landmark period) for patients eligible for SCT according to the existence of an allogeneic donor (N = 103 patients) (relative risk in the no-donor group, 1.71; 95% confidenced interval, 1.09 to 2.68; P = .02 by the log-rank test). Reprinted with permission [8].